At Ansun, we are committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients.
DISCOVERING SOLUTIONS FOR THE WORLD.
The Latest Technology for
preventing and treating life-threatening human diseases.
Company Updates:
-
Ansun is currently working with FDA to plan and implement a Phase 3 clinical trial of DAS181 for the treatment of PIV infection in hospitalized and immunocompromised patients.
-
DAS181 has received both Fast Track and Breakthrough Therapy designations by the U.S. FDA for this indication.
-
Ansun has observed activity of DAS181 against other important respiratory pathogens based on the same host-directed anti-viral mechanism.
